|
Tue, 07/07/2020 - 14:32 |
FDA Approves New Therapy for Myelodysplastic Syndromes (MDS) That Can Be Taken at Home |
FDA |
|
Thu, 05/14/2020 - 08:19 |
Tolero Pharmaceuticals Announces Expansion of the Zella 102 Study in Patients with Intermediate and High-Risk Myelodysplastic Syndromes (MDS) |
SDP Oncology |
|
Wed, 03/25/2020 - 21:35 |
Tolero Pharmaceuticals Joins The Leukemia & Lymphoma Societys Groundbreaking Beat AML Master Clinical Trial for Patients with Acute Myeloid Leukemia |
SDP Oncology |
|
Thu, 02/06/2020 - 16:12 |
Otsuka announces that subsidiary Astex Pharmaceuticals' NDA for ASTX727 (oral C-DEC), for the treatment of MDS and CMML, has been accepted for priority review by the U.S. FDA |
Otsuka |
|
Mon, 12/09/2019 - 11:32 |
A decades-long journey in blood cancer research |
Novartis |
|
Tue, 09/17/2019 - 17:01 |
Dana-Farber Cancer Institute receives $5 million gift to create the Edward P. Evans Center for Myelodysplastic Syndromes |
Dana Farber |
|
Tue, 09/03/2019 - 18:22 |
Astex Pharmaceuticals announces that its novel, oral hypomethylating agent ASTX727 has been granted orphan drug designation for the treatment of myelodysplastic syndromes (including chronic myelomonocytic leukemia) by the US FDA |
Astex |
|
Fri, 06/07/2019 - 12:28 |
Otsuka and Taiho Announce that Taiho Will Commercialize Two of Astex Pharmaceuticals' Drug Candidates in North America |
Otsuka |
|
Fri, 06/07/2019 - 12:22 |
Otsuka and its Subsidiary Astex Pharmaceuticals, Inc. Announce Positive Results from a Phase III Clinical Trial of Anticancer Candidate ASTX727 |
Otsuka |
|
Fri, 06/07/2019 - 05:38 |
Taiho Oncology Announces Agreement with Otsuka to Commercialize Astex Pharmaceuticals Drug Candidates |
Astex |
|
Thu, 12/20/2018 - 13:22 |
Daiichi Sankyo Initiates First Novel-Novel Combination Study of Two Investigational Agents within its AML Franchise in Patients with AML |
Daiichi Sankyo |
|
Thu, 11/29/2018 - 18:10 |
Venetoclax combination approved for elderly AML |
Dana Farber |
|
Wed, 11/21/2018 - 10:15 |
Roche announces FDA grants Venclexta accelerated approval for people with newly-diagnosed acute myeloid leukaemia or those who are ineligible for intensive induction chemotherapy |
Rocheusa |
|
Tue, 10/16/2018 - 08:28 |
Tolero Pharmaceuticals announces first patient dosed with investigational agent Alvocidib in phase 1b/2 Zella 102 study in patients with myelodysplastic syndromes (MDS) |
SDP Oncology |
|
Sun, 09/30/2018 - 18:31 |
Lupin receives FDA approval for Decitabine for Injection, 50 mg/vial, Single-Dose Vial |
Lupin |
|
Mon, 07/30/2018 - 03:07 |
Astex Pharmaceuticals and Otsuka announce results of the phase 3 ASTRAL-1 study of guadecitabine (SGI-110) in treatment-naive AML patients ineligible to receive intense induction chemotherapy |
Astex |
|
Thu, 05/18/2017 - 08:37 |
Helsinn Group and MEI Pharma Announce Upcoming Presentations of Gene Mutation and Clinical Response Data from Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia |
MEI Pharma |
|
Sat, 12/03/2016 - 07:28 |
Helsinn Group and MEI Pharma Report Prolongation of Survival Results from Phase 2 Clinical Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia |
MEI Pharma |
|
Tue, 11/29/2016 - 10:40 |
Astex to Showcase Its Next-Generation Hypomethylating Agents Being Developed for Treatment of AML/MDS at the 2016 Annual Meeting of the American Society of Hematology |
Astex |
|
Mon, 08/29/2016 - 11:26 |
Vitamin C may boost effectiveness of acute myeloid leukemia treatment |
Van Andel |
|
Mon, 08/08/2016 - 08:16 |
Helsinn Group and MEI Pharma Enter Strategic Agreement for the Development and Commercialization of Pracinostat for the Treatment of Acute Myeloid Leukemia and Other Hematologic Diseases |
MEI Pharma |
|
Mon, 08/01/2016 - 07:11 |
MEI Pharma's Pracinostat Receives Breakthrough Therapy Designation from FDA for Treatment in Combination with Azacitidine of Patients with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Chemotherapy |
MEI Pharma |
|
Mon, 12/07/2015 - 16:23 |
Combination Treatment with Decitabine Yields Higher Response for Patients with AML or MDS |
Fox Chase |
|
Wed, 04/22/2015 - 17:54 |
Study illuminates role of cancer drug decitabine in repairing damaged cells |
Purdue |
